prnewswire.comOrsini chosen by Ascendis to distribute treatment for rare endocrine disorder in the U.S.9 months ago
finance.yahoo.comAllarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program11 months ago
finance.yahoo.comBioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish11 months ago
CashuAscendis Pharma A/S Sees Short Interest Decline, Suggesting Positive Market Sentiment Shift3 days ago
CashuAscendis Pharma A/S: Decrease in Short Interest Signals Market Optimism and Growth Potential5 days ago
CashuAscendis Pharma A/S Sees 20.27% Drop in Short Interest, Boosting Investor Confidenceabout 2 months ago